Medical Condition News

RSS

Scientists create first 3-D image of key protein involved in development of cancers

Scientists from New Zealand and Australia have created the first three-dimensional image of a key protein involved in the development of blood and other cancers.

9 Oct 2015

Repatha (evolocumab) injection gets FDA approval for high cholesterol

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.

9 Oct 2015

Study: Women less likely than men to have good relief of chronic pain with long-term opioid use

Women, and especially younger women, are much less likely than men to have good relief of chronic, non-cancer pain with long-term opioid use, with only one in five women reporting low levels of pain and high levels of function with chronic opioid therapy in a new study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

9 Oct 2015

People with restless legs syndrome at higher risk for stroke, heart and kidney disease

Imagine trying to lie down and rest but feeling an uncontrollable urge to keep moving your legs. That, in a nutshell, is the ongoing ordeal facing people with restless legs syndrome. Considered a neurological, sleep, or movement disorder, RLS affects up to 1 in 10 people in the U.S. For those coping with a more severe form of RLS, countless sleepless nights--during which they may toss and turn constantly, or get up and pace the floor--can shatter quality of life.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Risk of having high blood pressure in adulthood can be detected in childhood

Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new research from New Zealand's University of Otago suggests.

9 Oct 2015

$Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study$

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Osteoporosis, a disease of progressive bone loss, affects 70 percent of the U.S. population older than age 50: one in two women--and one in five men. These individuals are at risk for fragility fractures, a break that results from a fall, or occurs in the absence of obvious trauma, and most commonly seen in the wrist, the upper arm, the hip, and the spine.

9 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

Antioxidants can increase rate of melanoma metastasis in mice

Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice. The results reinforce previous findings that antioxidants hasten the progression of lung cancer. According to Professor Martin Bergö, people with cancer or an elevated risk of developing the disease should avoid nutritional supplements that contain antioxidants.

9 Oct 2015

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF).

8 Oct 2015

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

Bankers Healthcare Group, the leading provider of financial solutions for healthcare professionals, recently launched a company-wide diabetes awareness campaign that will run through November.

8 Oct 2015

Up to 1 billion people could be at risk of going blind by 2050, say researchers

Up to 1 billion people could be at risk of blindness by the middle of the century if an emerging short-sightedness (myopia) epidemic is ignored say researchers at the Brien Holden Vision Institute.

8 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

Study assesses customer satisfaction with blood glucose meters

Training materials that are accessible and easy to understand contribute to an overall increase in satisfaction among adults or parents of children with Type 1 or Type 2 diabetes who use a blood glucose meter, and satisfaction is significantly higher when they understand how to use their meter, according to the J.D. Power 2015 U.S. Blood Glucose Meter Satisfaction Study.

8 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Boston Scientific closes additional financing with MValve Technologies

Boston Scientific Corporation today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS Valve, creating a unique mitral regurgitation (MR) treatment solution.

8 Oct 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

8 Oct 2015

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.

8 Oct 2015

Medical Condition News

Scientists create first 3-D image of key protein involved in development of cancers

Repatha (evolocumab) injection gets FDA approval for high cholesterol

Study: Women less likely than men to have good relief of chronic pain with long-term opioid use

People with restless legs syndrome at higher risk for stroke, heart and kidney disease

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Risk of having high blood pressure in adulthood can be detected in childhood

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Antioxidants can increase rate of melanoma metastasis in mice

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

Up to 1 billion people could be at risk of going blind by 2050, say researchers

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Study assesses customer satisfaction with blood glucose meters

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Boston Scientific closes additional financing with MValve Technologies

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News